<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Adoptively transferred immune cells in combination with chemotherapeutic agents form the basis for adoptive chemoimmunotherapy (ACIT) of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">neoplastic disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Autolymphocytes (ALT-cells) are ex vivo activated peripheral blood lymphocytes (PBL) from <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-bearing hosts (TBH) that consist primarily of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific CD45RO+ (memory) T-cells </plain></SENT>
<SENT sid="2" pm="."><plain>These ALT-cells combined with <z:chebi fb="1" ids="3699">cimetidine</z:chebi> (CIM) as autolymphocyte therapy (ALT), have previously been demonstrated to be a safe and active form of outpatient adoptive immunotherapy (AIT) in human TBH with <z:e sem="disease" ids="C0278678" disease_type="Neoplastic Process" abbrv="">metastatic renal cell cancer</z:e> (<z:chebi fb="60" ids="47899">RCC</z:chebi>) </plain></SENT>
<SENT sid="3" pm="."><plain>We have previously described an effective ACIT protocol using ALT and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CY) for patients with relapsed and refractory non-<z:chebi fb="60" ids="47899">RCC</z:chebi> <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We now report a case of a patient with a metastatic gastric <z:hpo ids='HP_0100243'>leiomyosarcoma</z:hpo> to the liver, who developed a clinical picture consistent with a <z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">tumor-lysis syndrome</z:e> (TLS), following salvage therapy for his <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> with ACIT using ALT and CY </plain></SENT>
<SENT sid="5" pm="."><plain>TLS is a well-known complication resulting from the treatment of rapidly proliferating <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic tumors</z:e> such as Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>TLS has also been rarely described in <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, as well as certain <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> such as <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, <z:e sem="disease" ids="C0149925" disease_type="Neoplastic Process" abbrv="SCLC">small cell lung cancer</z:e>, and <z:hpo ids='HP_0002885'>medulloblastoma</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>However, there have been no previous reports of TLS occurring either secondary to immunotherapy or in <z:hpo ids='HP_0100242'>sarcomas</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>The nature of these unusual findings is discussed </plain></SENT>
</text></document>